Renal replacement therapy and acute renal failure

Current Opinion in Pediatrics

Volumn 17, Issue 2, 2005, Pages 205-209

  Quan, Albert ^a   Quigley, Raymond ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE KIDNEY FAILURE; ARTIFICIAL KIDNEY; BIOARTIFICIAL ORGAN; BIOCOMPATIBILITY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIALYSIS; DIALYSIS MEMBRANE; EPIDEMIOLOGICAL DATA; GLOMERULUS FILTRATION RATE; HEMATOCRIT; HEMODIALYSIS; HEMODYNAMIC MONITORING; HEMOFILTRATION; HOSPITALIZATION; HUMAN; KIDNEY TUBULE CELL; META ANALYSIS; PATIENT MONITORING; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ULTRAFILTRATION;

CHILD; HUMANS; KIDNEY; KIDNEY FAILURE, ACUTE; RENAL DIALYSIS; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

EID: 17144408020     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000152995.81317.ae     Document Type: Review

References (44)

1. Mehta RL, Chertow GM. Acute renal failure definitions and classification: time for change? J Am Soc Nephrol 2003; 14:2178-2187. This is an excellent review of the many problems associated with the definitions of acute renal failure in many of the studies that have been performed.
2. Goldstein SL. Overview of pediatric renal replacement therapy in acute renal failure. Artif Organs 2003; 27:781-785. Provides an overview of the treatment modalities utilized in pediatric centers.
3. Williams DM, Sreedhar SS, Mickell JJ, Chan JC. Acute kidney failure: a pediatrie experience over 20 years. Arch Pediatr Adolesc Med 2002; 156:893-900.
4. Flynn JT. Choice of dialysis modality for management of pediatric acute renal failure. Pediatr Nephrol 2002; 17:61-69
5. Strazdins V, Watson AR, Harvey B. Renal replacement therapy for acute renal failure in children: European guidelines. Pediatr Nephrol 2004; 19:199-207. This is a review of the various modalities used to manage pediatric ARF. As with the other reviews, this is not a study comparing the modalities, but a review of the available techniques.
6. Bunchman TE. Plasmapheresis and rena replacement therapy in children. Curr Opin Pediatr 2002; 14:310-314.
7. Durmaz I, Yagdi T, Calkavur T, et al. Prophylactic dialysis in patients with renal dysfunction undergoing on-pump coronary artery bypass surgery. Ann Thorac Surg 2003; 75:859-864. The first trial examining the impact of the timing of initiation of dialysis on the outcome of patients with ARF.
8. Hoste EA, Lameire NH, Vanholder RC, et al. Acute renal failure, in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol 2003; 14:1022-1030.
9. Ichimura T, Hung CC, Yang SA, et al. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 2004; 286:F552-F563.
10. Westhuyzen J, Endre ZH, Reece G, et al. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol Dial Transplant 2003; 18:543-551.
11. Rosen S, Heyman S. Concerns about KIM 1 as a urinary biomarker for acute tubular necrosis (ATN). Kidney Int 2003; 63:1955.
12. De Vriese AS. Prevention and treatment of acute renal failure in sepsis. J Am Soc Nephrol 2003; 14:792-805.
13. Schulman G, Himmelfarb J. Hemodialysis. n: The kidney. 7 ed. Brenner BM, editor. Philadelphia: Saunders; 2004. pp 2563-2624.
14. Ikizler TA, Sezer MT, Flakoll PJ, et al. Urea space and total body water measurements by stable isotopes in patients with acute renal failure. Kidney Int 2004; 65:725-732.
15. Luyckx VA, Bonventre JV. Dose of dialysis in acute renal failure. Semin Dial 2004; 17:30-36.
16. Gillum DM, Dixon BS, Yanover MJ, et al. The role of intensive dialysis in acute renal failure. Clin Nephrol 1986; 25:249-255.
17. Leblanc M, Tapolyai M, Paganini EP. What dialysis dose should be provided in acute renal failure? A review. Adv Ren Replace Ther 1995; 2:255-264.
18. Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002; 346:305-310. This will prove to be a landmark study of the benefits of daily dialysis on the outcome of patients with ARF. It was a prospective study that clearly demonstrated what most nephrologists believed, which is that more dialysis is better.
19. Goldstein SL, Smith CM, Currier H. Noninvasive interventions to decrease hospitalization and associated costs for pediatric patients receiving hemodialysis. J Am Soc Nephrol 2003; 14:2127-2131.
20. Subramanian S, Venkataraman R, Kellum JA. Influence of dialysis membranes on outcomes in acute renal failure: a meta-analysis. Kidney Int 2002; 62:1819-1823.
21. Jaber BL, Lau J, Schmid CH, et al. Effect of biocompatibility of hemodialysis membranes on mortality in acute renal failure: a meta-analysis. Clin Nephrol 2002; 57:274-282.
22. Teehan GS, Liangos O, Lau J, et al. Dialysis membrane and modality in acute renal failure: understanding discordant meta-analyses. Semin Dial 2003; 16:356-360. Attempts to determine the differences in the above meta-analyses on the impact of dialysis membranes and outcome in the treatment of ARF.
23. Headrick CL, Alexander SR. Continuous veno-venous hemofiltration. In: Levin DL, Morriss FC, editors. Essentials in pediatric intensive care. 2nd ed. New York: Churchill, Livingston; Quality Medical Publishing, Inc.; 1997. pp 1602-1627.
24. Clark WR, Turk JE, Kraus MA, Gao D. Dose determinants in continuous renal replacement therapy. Artif Organs 2003; 27:815-820.
25. Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, et al. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med 2002; 30:2205-2211.
26. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356:26-30.
27. Brause M, Neumann A, Schumacher T, et al. Effect of filtration volume of continuous venovenous hemofiltration in the treatment of patients with acute renal failure in intensive care units. Crit Care Med 2003; 31:841-846.
28. Ronco C, Tetta C, Mariano F, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 2003; 27:792-801. Review of the evidence for the hypothesis that filtration removes some of the mediators of sepsis.
29. Troyanov S, Cardinal J, Geadah D, et al. Solute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF1000 filters. Nephrol Dial Transplant 2003; 18:961-966.
30. Guerin C, Girard R, Selli JM, Ayzac L. Intermittent versus continuous renal replacement therapy for acute renal failure in intensive care units: results from a multicenter prospective epidemiological survey. Intensive Care Med 2002; 28:1411-1418.
31. Kellum JA, Angus DC, Johnson JP, et al. Continuous versus intermittent renal replacement therapy: a meta-analysis. Intensive Care Med 2002; 28:29-37.
32. Tonelli M, Manns B, Feller-Kopman D. Acute renal failure in the intensive care unit, a systematic review of the impact of dialytic modality on mortality and renal recovery. Am J Kidney Dis 2002; 40:875-885.
33. Marshall MR, Ma T, Galler D, et al. Sustained low-efficiency daily diafiltration (SLEDD-f) for critically ill patients requiring renal replacement therapy: towards an adequate therapy. Nephrol Dial Transplant 2004; 19:877-884.
34. Humes HD, Weitzel WF, Fissell WH. Renal cell therapy in the treatment of patients with acute and chronic renal failure. Blood Purif 2004; 22: 60-72.
35. Humes HD, Fissell WH, Weitzel WF. The bioartificial kidney in the treatment of acute renal failure. Kidney Int Suppl 2002; 121-125.
36. Humes HD, Buffington DA, Lou L, et al. Cell therapy with a tissue-engineered kidney reduces the multiple-organ consequences of septic shock. Crit Care Med 2003; 31:2421-2428.
37. Fissell WH, Lou L, Abrishami S, et al. Bioartificial kidney ameliorates gram-negative bacteria-induced septic shock in uremic animals. J Am Soc Nephrol 2003; 14:454-461.
38. Humes HD. Cell therapy: leveraging nature's therapeutic potential. J Am Soc Nephrol 2003; 14:2211-2213.
39. Humes HD, Weitzel WF, Bartlett RH, et al. Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int 2004; 66:1578-1588. The bioartificial kidney has now undergone initial Phase I/II clinical trials in humans. Because of the small number of patients, it was difficult to demonstrate any benefit. However, this appears to be a promising avenue for development.
40. Quan A. Peritoneal dialysis. In: Levin DL, Morriss FC, editors. Essentials of pediatric intensive care. 2nd ed. New York: Churchill, Livingston; Quality Medical Publishing, Inc.; 1997. pp 1576-1589.
41. Wolfson M, Piraino B, Hamburger RJ, Morton AR. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 2002; 40:1055-1065.
42. Konings CJ, Kooman JP, Schonck M, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int 2003; 63:1556-1563.
43. Johnson DW, Arndt M, O'Shea A, et al. Icodextrin as salvage therapy in peritoneal dialysis patients with refractory fluid overload. BMC Nephrol 2001; 2:2.
44. Veltri MA, Neu AM, Fivush BA, et al. Drug dosing during intermittent hemodialysis and continuous renal replacement therapy: special considerations in pediatric patients. Paediatr Drugs 2004; 6:45-65. Drug dosing on the various renal replacement therapies can be problematic. This excellent review is very comprehensive in its effort to provide up-to-date information on the clearance of most drugs in pediatric patients on RRT.